UPDATE: Jefferies Initiates Anthera Pharmaceuticals at Buy on Blisibimod Outlook

Jefferies initiated coverage on Anthera Pharmaceuticals (NASDAQ: ANTH ) with a Buy rating and a $2.00 price target. Jefferies noted, "Despite conducting a well randomized Phase II trial, and improving its Phase III odds by identifying a more targeted lupus patient population, Anthera trades at a ~$50 million EV (v